DVA vs. TEVA: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at DVA and TEVA, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
DVA is a standard domestic listing, while TEVA trades as an American Depositary Receipt (ADR), offering U.S. investors access to its foreign-listed shares.
| Symbol | DVA | TEVA |
|---|---|---|
| Company Name | DaVita Inc. | Teva Pharmaceutical Industries Limited |
| Country | United States | Israel |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Health Care Providers & Services | Pharmaceuticals |
| Market Capitalization | 9.84 billion USD | 20.76 billion USD |
| Exchange | NYSE | NYSE |
| Listing Date | October 31, 1995 | February 16, 1982 |
| Security Type | Common Stock | ADR |
Historical Performance
This chart compares the performance of DVA and TEVA by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | DVA | TEVA |
|---|---|---|
| 5-Day Price Return | -0.01% | -3.07% |
| 13-Week Price Return | -1.67% | -2.13% |
| 26-Week Price Return | -3.40% | 1.54% |
| 52-Week Price Return | -11.11% | -11.44% |
| Month-to-Date Return | -2.00% | 8.44% |
| Year-to-Date Return | -8.02% | -25.11% |
| 10-Day Avg. Volume | 0.66M | 1.66M |
| 3-Month Avg. Volume | 0.82M | 2.25M |
| 3-Month Volatility | 31.04% | 25.51% |
| Beta | 1.15 | 0.82 |
Profitability
Return on Equity (TTM)
DVA
181.22%
Health Care Providers & Services Industry
- Max
- 26.03%
- Q3
- 13.74%
- Median
- 8.26%
- Q1
- 4.13%
- Min
- -3.62%
DVA’s Return on Equity of 181.22% is exceptionally high, placing it well beyond the typical range for the Health Care Providers & Services industry. This demonstrates a superior ability to generate profit from shareholder investments, though it could also be inflated by high financial leverage.
TEVA
-2.58%
Pharmaceuticals Industry
- Max
- 38.59%
- Q3
- 19.84%
- Median
- 11.90%
- Q1
- 5.63%
- Min
- -9.96%
TEVA has a negative Return on Equity of -2.58%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.
Net Profit Margin (TTM)
DVA
6.35%
Health Care Providers & Services Industry
- Max
- 12.40%
- Q3
- 5.93%
- Median
- 1.96%
- Q1
- 0.93%
- Min
- -6.10%
A Net Profit Margin of 6.35% places DVA in the upper quartile for the Health Care Providers & Services industry, signifying strong profitability and more effective cost management than most of its peers.
TEVA
-0.95%
Pharmaceuticals Industry
- Max
- 34.51%
- Q3
- 17.73%
- Median
- 12.12%
- Q1
- 5.99%
- Min
- -7.73%
TEVA has a negative Net Profit Margin of -0.95%, indicating the company is operating at a net loss as its expenses exceeded its revenues.
Operating Profit Margin (TTM)
DVA
15.70%
Health Care Providers & Services Industry
- Max
- 19.05%
- Q3
- 10.21%
- Median
- 4.22%
- Q1
- 1.98%
- Min
- -4.27%
An Operating Profit Margin of 15.70% places DVA in the upper quartile for the Health Care Providers & Services industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
TEVA
5.38%
Pharmaceuticals Industry
- Max
- 41.53%
- Q3
- 23.00%
- Median
- 16.24%
- Q1
- 9.24%
- Min
- -6.94%
TEVA’s Operating Profit Margin of 5.38% is in the lower quartile for the Pharmaceuticals industry. This indicates weaker profitability from core operations, which may stem from inefficiencies or competitive pressures on pricing.
Profitability at a Glance
| Symbol | DVA | TEVA |
|---|---|---|
| Return on Equity (TTM) | 181.22% | -2.58% |
| Return on Assets (TTM) | 4.82% | -0.40% |
| Net Profit Margin (TTM) | 6.35% | -0.95% |
| Operating Profit Margin (TTM) | 15.70% | 5.38% |
| Gross Profit Margin (TTM) | 32.54% | 50.88% |
Financial Strength
Current Ratio (MRQ)
DVA
1.39
Health Care Providers & Services Industry
- Max
- 2.01
- Q3
- 1.49
- Median
- 1.30
- Q1
- 0.94
- Min
- 0.17
DVA’s Current Ratio of 1.39 aligns with the median group of the Health Care Providers & Services industry, indicating that its short-term liquidity is in line with its sector peers.
TEVA
1.06
Pharmaceuticals Industry
- Max
- 4.49
- Q3
- 2.77
- Median
- 1.74
- Q1
- 1.26
- Min
- 0.11
TEVA’s Current Ratio of 1.06 falls into the lower quartile for the Pharmaceuticals industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
Debt-to-Equity Ratio (MRQ)
DVA
77.99
Health Care Providers & Services Industry
- Max
- 2.17
- Q3
- 1.18
- Median
- 0.74
- Q1
- 0.45
- Min
- 0.00
With a Debt-to-Equity Ratio of 77.99, DVA operates with exceptionally high leverage compared to the Health Care Providers & Services industry norm. This suggests an aggressive reliance on debt financing, which can magnify returns but also significantly elevates financial risk.
TEVA
2.52
Pharmaceuticals Industry
- Max
- 2.44
- Q3
- 1.07
- Median
- 0.42
- Q1
- 0.11
- Min
- 0.00
With a Debt-to-Equity Ratio of 2.52, TEVA operates with exceptionally high leverage compared to the Pharmaceuticals industry norm. This suggests an aggressive reliance on debt financing, which can magnify returns but also significantly elevates financial risk.
Interest Coverage Ratio (TTM)
DVA
4.44
Health Care Providers & Services Industry
- Max
- 14.47
- Q3
- 7.15
- Median
- 5.45
- Q1
- 2.04
- Min
- -4.44
DVA’s Interest Coverage Ratio of 4.44 is positioned comfortably within the norm for the Health Care Providers & Services industry, indicating a standard and healthy capacity to cover its interest payments.
TEVA
-0.38
Pharmaceuticals Industry
- Max
- 103.95
- Q3
- 44.18
- Median
- 9.83
- Q1
- 2.82
- Min
- -42.71
TEVA has a negative Interest Coverage Ratio of -0.38. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.
Financial Strength at a Glance
| Symbol | DVA | TEVA |
|---|---|---|
| Current Ratio (MRQ) | 1.39 | 1.06 |
| Quick Ratio (MRQ) | 1.31 | 0.68 |
| Debt-to-Equity Ratio (MRQ) | 77.99 | 2.52 |
| Interest Coverage Ratio (TTM) | 4.44 | -0.38 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
DVA
0.00%
Health Care Providers & Services Industry
- Max
- 5.38%
- Q3
- 2.22%
- Median
- 0.55%
- Q1
- 0.00%
- Min
- 0.00%
DVA currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
TEVA
0.00%
Pharmaceuticals Industry
- Max
- 6.98%
- Q3
- 3.32%
- Median
- 2.13%
- Q1
- 0.14%
- Min
- 0.00%
TEVA currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
Dividend Payout Ratio (TTM)
DVA
0.00%
Health Care Providers & Services Industry
- Max
- 186.69%
- Q3
- 74.82%
- Median
- 26.76%
- Q1
- 0.00%
- Min
- 0.00%
DVA has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
TEVA
0.00%
Pharmaceuticals Industry
- Max
- 165.20%
- Q3
- 90.59%
- Median
- 49.13%
- Q1
- 28.91%
- Min
- 0.00%
TEVA has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
Dividend at a Glance
| Symbol | DVA | TEVA |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
Price-to-Earnings Ratio (TTM)
DVA
11.71
Health Care Providers & Services Industry
- Max
- 55.89
- Q3
- 30.85
- Median
- 21.17
- Q1
- 12.63
- Min
- 0.00
In the lower quartile for the Health Care Providers & Services industry, DVA’s P/E Ratio of 11.71 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.
TEVA
--
Pharmaceuticals Industry
- Max
- 42.51
- Q3
- 26.88
- Median
- 19.11
- Q1
- 15.12
- Min
- 0.00
P/E Ratio data for TEVA is currently unavailable.
Price-to-Sales Ratio (TTM)
DVA
0.74
Health Care Providers & Services Industry
- Max
- 3.10
- Q3
- 1.74
- Median
- 0.67
- Q1
- 0.24
- Min
- 0.00
DVA’s P/S Ratio of 0.74 aligns with the market consensus for the Health Care Providers & Services industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
TEVA
1.25
Pharmaceuticals Industry
- Max
- 7.55
- Q3
- 4.54
- Median
- 2.11
- Q1
- 1.52
- Min
- 0.00
In the lower quartile for the Pharmaceuticals industry, TEVA’s P/S Ratio of 1.25 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.
Price-to-Book Ratio (MRQ)
DVA
101.25
Health Care Providers & Services Industry
- Max
- 7.61
- Q3
- 4.32
- Median
- 2.53
- Q1
- 1.14
- Min
- 0.77
At 101.25, DVA’s P/B Ratio is at an extreme premium to the Health Care Providers & Services industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.
TEVA
2.80
Pharmaceuticals Industry
- Max
- 9.78
- Q3
- 4.96
- Median
- 2.23
- Q1
- 1.46
- Min
- 0.60
TEVA’s P/B Ratio of 2.80 is within the conventional range for the Pharmaceuticals industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
Valuation at a Glance
| Symbol | DVA | TEVA |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 11.71 | -- |
| Price-to-Sales Ratio (TTM) | 0.74 | 1.25 |
| Price-to-Book Ratio (MRQ) | 101.25 | 2.80 |
| Price-to-Free Cash Flow Ratio (TTM) | 7.60 | 18.48 |